Multivalency - A way to enhance binding avidities and bioactivity - Preliminary applications to EPO

Journal of Peptide Science

Volumn 13, Issue 9, 2007, Pages 581-587

  Vadas, Oscar ^a   Rose, Keith ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Erythropoietin; Multivalency; Oxime; Peptide synthesis

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN MIMETIC PEPTIDE; ERYTHROPOIETIN RECEPTOR; ERYTHROPOIETIN RECEPTOR PEPTIDE; HETERODIMER; HOMODIMER; PEPTIDE; POLYAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; DISULFIDE BOND; DRUG SYNTHESIS; LIGAND BINDING; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN TARGETING;

AMINO ACID SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIMERIZATION; ERYTHROPOIETIN, RECOMBINANT; HUMANS; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, QUATERNARY; RECEPTORS, ERYTHROPOIETIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34848873423     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.794     Document Type: Article

References (29)

1. Kitov PI, Bundle DR. On the nature of the multivalency effect: a thermodynamic model. J. Am. Chem. Soc. 2003; 125: 16271-16284.
2. Terskikh AV, Le Doussal JM, Crameri R, Fisch I, Mach JP, Kajava AV. "Peptabody": a new type of high avidity binding protein. Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 1663-1668.
3. Kramer RH, Karpen JW. Spanning binding sites on allosteric proteins with polymer-linked ligand dimers. Nature 1998; 395: 710-713.
4. Rao J, Lahiri J, Weis RM, Whitesides GM. Design, synthesis, and characterization of a high-affinity trivalent system derived from vancomycin and L-Lys-D-Ala-D-Ala. J. Am Chem. Soc. 2000; 122: 2698-2710.
5. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM, Schatz PJ, Baccanari DP, Wrighton NC, Barrett RW, Dower WJ. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276: 1696-1699.
6. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Kroon D, Freedy J, Zivin RA, Mulcahy LS, Jolliffe LK. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem. Biol. 1997; 4: 939-950.
7. Krantz SB. Erythropoietin. Blood 1991; 77: 419-434.
8. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat. Clin. Pract. Oncol. 2006; 3: 152-164.
9. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 2003; 31: 290-299.
10. Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN. Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity. Exp. Hematol. 2006; 34: 697-704.
11. Kochendoerfer GG, Chen SY, Mao F, Cressman S, Traviglia S, Shao H, Hunter CL, Low DW, Cagle EN, Carnevali M, Gueriguian V, Keogh PJ, Porter H, Stratton SM, Wiedeke MC, Wilken J, Tang J, Levy JJ, Miranda LP, Crnogorac MM, Kalbag S, Botti P, Schindler-Horvat J, Savatski L, Adamson JW, Kung A, Kent SB, Bradburne JA. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 2003; 299: 884-887.
12. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999; 283: 987-990.
13. Naranda T, Wong K, Kaufman RI, Goldstein A, Olsson L. Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site. Proc. Natl. Acad. Sci. U.S.A. 1999; 96: 7569-7574.
14. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J. Biol. Chem. 1999; 274: 24773-24778.
15. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 1184-1188.
16. Dalle B, Henri A, Rouyer-Fessard P, Bettan M, Scherman D, Beuzard Y, Payen E. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood 2001; 97: 3776-3782.
17. Rose K, Vizzavona J. Stepwise solid-phase synthesis of polyamides as linkers. J. Am. Chem. Soc. 1999; 121: 7034-7038.
18. Baessler KA, Lee Y, Roberts KS, Facompre N, Sampson NS. Multivalent fertilinbeta oligopeptides: the dependence of fertilization inhibition on length and density. Chem Biol. 2006; 13: 251-259.
19. Fields G. Solid phase peptide synthesis. Methods Enzymol. 1997; 289: 3-392.
20. Schnolzer M, Alewood P, Jones A, Alewood D, Kent SB. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 1992; 40: 180-193.
21. Rose K. Facile synthesis of homogeneous artificial proteins. J. Am. Chem. Soc. 1994; 116: 30-33.
22. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970; 34: 595-598.
23. Gaertner HF, Offord RE. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjugate Chem. 1996; 7: 38-44.
24. Gaertner HF, Rose K, Cotton R, Timms D, Camble R, Offord RE. Construction of protein analogues by site-specific condensation of unprotected fragments. Bioconjugate Chem. 1992; 3: 262-268.
25. Kieran FG, Stroh JG. Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine. Bioconjugate Chem. 1992; 3: 138-146.
26. Naranda T, Kaufman RI, Li J, Wong K, Boge A, Hallen D, Fung KY, Duncan MW, Andersen N, Goldstein A, Olsson L. Activation of erythropoietin receptor through a novel extracellular binding site. Endocrinology 2002; 143: 2293-2302.
27. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996; 273: 464-471.
28. Nardin EH, Calvo-Calle JM, Oliveira GA, Nussenzweig RS, Schneider M, Tiercy JM, Loutan L, Hochstrasser D, Rose K. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 2001; 166: 481-489.
29. Zeng W, Ghosh S, Macris M, Pagnon J, Jackson DC. Assembly of synthetic peptide vaccines by chemoselective ligation of epitopes: influence of different chemical linkages and epitope orientations on biological activity. Vaccine 2001; 19: 3843-3852.